The No. 1 Insider Stock for 2024?

Artificial intelligence is revolutionizing this industry - leading to big profits... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

View in browser SPONSORED Emmy Award-Winning Journalist Exposes Truth Behind Popular Trading Breakthrough Emmy & Peabody Award-winning financial journalist behind Lou Dobbs's success sat down with a reclusive trader... Who recently developed a strategy that outperformed the market by the 1,700% to start the year... To see why thousands of traders keep raving about this new approach. Is it the real deal? See His Findings Here EDITOR'S NOTE In 2018, a small group of insiders loaded up on nearly $4 million worth of stock in a little-known company called Tandem Diabetes Care (Nasdaq: TNDM). Those who followed their lead saw the chance to turn $10,000 into $189,000 in just one year. That's a staggering 1,795% gain! Alexander Green has been tracking insider moves like this for decades, and he's ready to share his next big insider opportunity with you. Click here to see details on Alex's top insider stock pick right now... completely free of charge. - Nicole Labra, Senior Managing Editor THE SHORTEST WAY TO A RICH LIFE Could This Be the Best Insider Stock for 2024? Alexander Green, Chief Investment Strategist, The Oxford Club Over the past decade, investing in biotech stocks with insider buying has tripled the S&P 500's return. Tandem Diabetes Care (Nasdaq: TNDM) and Exscientia PLC (Nasdaq: EXAI) are prime examples of some I've recommended. The former was a particularly big winner, allowing my readers to lock in up to a 1,795% gain in less than one year. Needless to say, I'm bullish on the industry. But there's one big problem faced by most biotechs: Drug discovery. More specifically, how long drug discovery takes and how much it costs. Drug discovery hasn't changed much in the last century. It still takes up to a decade or even more in some cases to develop a new drug. It's a long, manual process with lots of trial and error (not to mention government red tape) that can be performed only by highly trained resources. Because of that, it's also astronomically expensive. The average cost to develop a new drug is $2.6 billion... That's a lot of money to shell out for a drug that may not even make the cut - a full 9 out of 10 drugs entering Phase 1 clinical trials never make it to market. They get shot down by the Food and Drug Administration (FDA), often for good reason. But by that point, it's already cost billions of dollars to develop them.That's changing, though. And it's changing fast. Artificial intelligence (AI) can make drug development a faster and cheaper process with fewer costly failures. It can shorten drug development times from a decade-plus on average to just a few short years and give us better, longer, healthier lives in the process. And this company is using AI to support the entire biotech industry. Because, unlike many biotech companies that focus on only one specific segment of the drug development process, this company helps other biotechs make new breakout discoveries. SPONSORED Famous Georgia Trader Reveals #1 Trade On Monday, Monday, July 15 The man who once turned $37k into $2.7 Million in just 4 years and recently closed a 1,129% win after just TWO days on a livestream.. Just revealed the #1 trade to make on Monday, Monday, July 15... All using a strategy that has produced an 81% win-rate over the past year. See his strategy here. In fact, it has supported 80% of all FDA-approved novel drugs that have hit the market over the past five years. If you're taking a new drug, there's a good chance this company helped develop it. I'm expecting big things for this company because its insiders are piling in at a breakneck pace... I think the biggest growth is just on the horizon. That's based on the fact that insiders have loaded up on $1.45 million worth of shares in the last 12 months - with some of the fastest buying happening as we were coming into the end of 2023. Among the biggest purchases were those from the CEO, who bought 5,620 shares for just over $1 million, and the COO, who bought 1,322 shares for just under $250,000 - both in November 2023. That's a prime example of the cluster buying that I look for - and from two of the highest-ranking executives at the company to boot... And when I see high-level insiders plunk down big money on their own stocks, I know something big is likely to happen soon... Following the Insiders This company sits at a crossroads of AI, biotech and insider buying: two industries growing at an incredible pace plus the single greatest indicator I've ever seen in the market... All in one stock. The company's incredible technology and the niche it's carved out in the biotech industry make it a great investment... But considering two of its highest-ranking executives are eating their own cooking to the tune of $1.2 million, this goes from a great buy to an out-and-out incredible opportunity. I'm bullish on the biotech industry, I'm bullish on AI and I've always been bullish on companies with massive insider purchases. This is not an opportunity you want to pass up, and it's my No. 1 insider stock pick for this year. [Find out more details here now.] This strategy has delivered gains as high as 1,163% in just 90 days. And today, I'm seeing signs that we could be on the verge of another massive winner. Click here to learn how you could potentially target 10X gains by Labor Day. Good investing, Alex Leave a Comment BUILD AND PROTECT YOUR WEALTH This Company Just Solved Europe's Energy Crisis... Wall Street Now Projects a Near 10-Fold Rise in 18 Months. Intel, Nvidia among top movers after Nasdaq and S&P surge. He Called Apple, Amazon, Netflix and Nvidia Over 20 Years Ago. Now He Says to Buy AI's "Next Magnificent Seven" Stocks. Two New Deals... JOIN THE CONVERSATION Facebook LinkedIn Email Share MORE FROM LIBERTY THROUGH WEALTH How Traders Can Earn Higher Short-Term Returns Earnings Season Has Arrived These Sectors Are About to Surge This Is What's So Great About America SPONSORED New Bitcoin Projection: $165,000 in the Next 18 Months New Bitcoin ETFs... Trillions in Cash Pouring in... Crypto is Set to Experience Another Major Bull Run. And It's One Particular Catalyst That Could Set Off a New Run Projected to Hit $165,000 Per Coin. See Why This Will Send Crypto Soaring Again Here. You are receiving this email because you subscribed to Liberty Through Wealth. Liberty Through Wealth is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Liberty Through Wealth | Unsubscribe © 2024 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 877.806.4508 | International: +1.443.353.4610 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.